BNP Paribas Financial Markets
IMPL

BNP Paribas Financial Markets’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

BNP Paribas Financial Markets’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,369
Closed -$6.67K – 4807
2022
Q3 		$6.67K Buy
+1,369
New +$10.5K ﹤0.01% 4224

Other funds holding IMPL

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Financial Markets's IMPL Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2022, closing a stake of 1,369 shares — an estimated $6.67K sold.

BNP Paribas Financial Markets first reported a position in IMPL in Q3 2022 and held it in 1 quarter. The position peaked at $6.67K in Q3 2022. 35 funds tracked by Wall St. Rank hold IMPL as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,369 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2022, an estimated $6.67K.
  • BNP Paribas Financial Markets first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Impel Pharmaceuticals Inc. Common Stock position peaked at $6.67K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.